Zhiwei Hu, MD, PhD
College of Medicine
Res Assoc Professor
Cancer, Breast Cancer, Choroidal Neovascularization, Macular Degeneration, Melanoma, Lung Cancer, Neoplasm Metastasis, Necrosis, Cancer, Vascular Tissue
Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature for development of novel dual neovascular- and cancer cell-targeted therapy for cancer. The Icon that Dr. Hu co-invented is one such dual-targeting agent. Icon has been tested as an immunotherapy for treatment of cancer, macular degeneration and endometriosis in preclinical studies as well as in Phase I clinical trial (for wet-form macular degeneration patients). Recently his laboratory co-developed another dual-targeted therapeutics, namely factor VII (fVII)-targeted photodynamic therapy (PDT) using fVII peptides-conjugated photosensitizer verteporfin or Sn (IV) chlorin e6 for cancer (including chemoresistant breast cancer) and macular degeneration. As co-inventor Dr. Hu holds 5 US patents for Icon and its uses. His laboratory is currently focusing on elucidating the mechanisms of action and exploring different ways to improve therapeutic efficacy. Dr. Hu is actively collaborating with renowned OSU physician scientists and researchers to translate fVII-targeted immunotherapy and PDT into clinical trials. His laboratory is also interested in study of tumor angiogenesis, natural killer cells and cancer stem cells and their interaction in tumor microenvironment.